Anzeige
Mehr »
Login
Sonntag, 05.05.2024 Börsentäglich über 12.000 News von 685 internationalen Medien
Cannabisaktien sollten nun den S&P um 60% outperformen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

GlobeNewswire (Europe)-Archiv vom 04.11.2023

ZeitNachrichten
Sprache: Alle DE EN
LeserMedien
04.11.23Adverum Biotechnologies, Inc.: Adverum Biotechnologies Announces 3-Year Efficacy and Safety Results from the OPTIC Extension Study in Patients with Wet AMD at AAO 2023266- Patients in OPTIC continue to experience long-term benefit from Ixo-vec through 3 years of follow-up, including maintenance of vision, durability of anatomical improvements and sustained reduction...
► Artikel lesen
04.11.23Candel Therapeutics Presents Preclinical Data from its enLIGHTEN Discovery Platform at SITC263The first experimental agent from the enLIGHTEN Discovery Platform is Alpha-201-macro1, an investigational viral immunotherapy designed to activate innate immune surveillanceApplication of the enLIGHTEN...
► Artikel lesen
04.11.23Gamida Cell, Ltd: Gamida Cell Presents New Data on Allogeneic Stem Cell Therapy Omidubicel and Natural Killer (NK) Cell Therapy Candidate GDA-201 at Society for Immunotherapy of Cancer (SITC) Annual Meeting203BOSTON, Nov. 04, 2023 (GLOBE NEWSWIRE) -- Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today shared new data on the impact of the company's...
► Artikel lesen
04.11.23Medigene AG: Medigene presents new data for MDG2011, the first TCR in a novel KRAS library, demonstrating capability of its proprietary E2E Platform to generate multiple enhanced TCR-T therapies against mKRAS G12V A11402Planegg/Martinsried, November 4, 2023. Medigene AG (Medigene, the "Company", FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies...
► Artikel lesen
04.11.23Vera Therapeutics Presents Positive Data from Phase 2b ORIGIN Study Showing Resolution of Hematuria in Majority of Patients at the American Society of Nephrology Kidney Week 2023 155Analysis of week 36 data from Phase 2b ORIGIN study shows atacicept 150 mg substantially reduces serum Gd-IgA1 and resolves hematuria in the majority of patients. Additional poster presentations...
► Artikel lesen
04.11.23Blender Bites Limited: Blender Bites Signs Definitive Agreement to Acquire Advanced Sports Nutrition Inc. and Targets Athletic Recovery with NFL-Funded Clinical Trial1.105VANCOUVER, British Columbia, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Blender Bites Limited. (the "Company", "Blender Bites" or "Blender"), (CSE: BITE, FWB: JL4, WKN: A3DMEJ), is excited to announce it has...
► Artikel lesen
04.11.23Replimune Group Inc: Replimune Presents Updated Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers During Oral Presentation at the 38th Annual Meeting of the Soc527WOBURN, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies...
► Artikel lesen
04.11.23The Honest Company, Inc.: The Honest Company Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)644LOS ANGELES, Nov. 03, 2023 (GLOBE NEWSWIRE) -- The Honest Company (NASDAQ: HNST), a digitally-native consumer products company dedicated to creating clean- and sustainably-designed products spanning...
► Artikel lesen
04.11.23Grupo Aeroportuario del Pacífico, S.A.B. de C.V.: Grupo Aeroportuario Del Pacifico Reports in October 2023 a Passenger Traffic Increase of 4.7% Compared to 2022520GUADALAJARA, Mexico, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Grupo Aeroportuario del Pacífico, S.A.B. de C.V., (NYSE: PAC; BMV: GAP) ("the Company" or "GAP") announces preliminary terminal passenger traffic...
► Artikel lesen